In the WD + CCL4 model, simultaneously intervention with CCL4 and compounds suggests that CS27109 potentially prevents progression from liver steatohepatitis to fibrosis, whether its therapeutic effect in this model is still undefined. Here, CCL4 is linked to Wilson disease.